Capillary leak syndrome in neuromyelitis optica treated with rituximab


      • Rituximab (RTX) is considered to be an efficient and safe treatment for neuromyelitis optica (NMO).
      • Capillary leak syndrome (CLS) can be secondary to some medications.
      • There are only two fatal complications in NMO patient treated with RTX reported.
      • One case of CLS in NMO patient after rituximab treatment is presented.
      • Relationship between RTX and CLS causation is suggested.


      61-year-old woman with Neuromyelitis optica (NMO) diagnosis treated with rituximab was referred to our hospital with severe hypovolemic shock and anasarca. The laboratory findings showed marked hemoconcentration and a decrease in total serum protein. She developed a multiple organ failure and died three hours later. We diagnosed the patient as having capillary leak syndrome (CLS). CLS is a very rare condition caused by unexplained episodic capillary hyperpermeability, which can be idiopathic or secondary to some conditions like infection, malignant disease and some drugs like monoclonal antibodies. We reported the first CLS case in NMO patient treated with rituximab.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Collongues N.
        • de Seze J.
        An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica.
        Ther. Adv. Neurol. Disord. 2016; 9: 180-188
        • Jacob A.
        • Weinshenker B.G.
        • Violich I.
        • McLinskey N.
        • Krupp L.
        • Fox R.J.
        • et al.
        Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.
        Arch. Neurol. 2008; 65: 1443-1448
        • Kasi P.M.
        • Tawbi H.A.
        • Oddis C.V.
        • Kulkarni H.S.
        Clinical review: serious adverse events associated with the use of rituximab - a critical care perspective.
        Crit. Care. 2012; 16: 231
        • Pellkofer H.L.
        • Krumbholz M.
        • Berthele A.
        • Hemmer B.
        • Gerdes L.A.
        • Havla J.
        • et al.
        Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab.
        Neurology. 2011; 76: 1310-1315
        • Siddall E.
        • Khatri M.
        • Radhakrishnan J.
        Capillary leak syndrome: etiologies, pathophysiology, and management.
        Kidney Int. 2017;
      1. Yardimci B., Kazancioglu R., 2016. Idiopathic systemic capillary leak syndrome: a case report. Iran Red Crescent Med J [Internet]. Feb 20 (cited 2017 May 7);18(2). Available from: 〈〉.